NASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis $48.20 +0.20 (+0.42%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About Doximity Stock (NASDAQ:DOCS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Doximity alerts:Sign Up Key Stats Today's Range$47.72▼$48.6450-Day Range$39.44▼$61.2552-Week Range$22.96▼$61.75Volume2.14 million shsAverage Volume2.39 million shsMarket Capitalization$9.00 billionP/E Ratio55.40Dividend YieldN/APrice Target$52.27Consensus RatingHold Company OverviewDoximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More… Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video Doximity Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreDOCS MarketRank™: Doximity scored higher than 63% of companies evaluated by MarketBeat, and ranked 455th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 6 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageDoximity has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Doximity's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.30% Earnings GrowthEarnings for Doximity are expected to grow by 9.30% in the coming year, from $0.86 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 55.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 55.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.25.Price to Earnings Growth RatioDoximity has a PEG Ratio of 3.89. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 9.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Doximity's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DOCS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DOCS. News and Social Media3.2 / 5News Sentiment0.69 News SentimentDoximity has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Doximity this week, compared to 8 articles on an average week.Search Interest24 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows31 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 520% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have not sold or bought any company stock.Percentage Held by Insiders37.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Doximity's insider trading history. Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address DOCS Stock News HeadlinesJPMorgan Chase & Co. Boosts Doximity (NASDAQ:DOCS) Price Target to $48.00November 24 at 4:19 AM | americanbankingnews.comDoximity price target raised to $48 from $30 at JPMorganNovember 22 at 12:23 AM | markets.businessinsider.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 24, 2024 | Priority Gold (Ad)DOXIMITY INVESTOR NOTICE: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties - DOCSNovember 20, 2024 | markets.businessinsider.comPolen U.S. Small Company Growth Strategy Exited Doximity (DOCS) Due to Multiple FactorsNovember 19, 2024 | msn.comThe Goldman Sachs Group Initiates Coverage on Doximity (NASDAQ:DOCS)November 19, 2024 | americanbankingnews.comDoximity's (DOCS) "Hold" Rating Reiterated at Canaccord Genuity GroupNovember 17, 2024 | americanbankingnews.comDoximity initiated with a Neutral at Goldman SachsNovember 16, 2024 | markets.businessinsider.comSee More Headlines DOCS Stock Analysis - Frequently Asked Questions How have DOCS shares performed this year? Doximity's stock was trading at $28.04 at the beginning of 2024. Since then, DOCS shares have increased by 71.9% and is now trading at $48.20. View the best growth stocks for 2024 here. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) announced its quarterly earnings results on Tuesday, November, 9th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.13. The business had revenue of $79.35 million for the quarter, compared to the consensus estimate of $73.60 million. Doximity had a net margin of 33.69% and a trailing twelve-month return on equity of 19.79%. When did Doximity IPO? Doximity (DOCS) raised $501 million in an initial public offering on Thursday, June 24th 2021. The company issued 23,300,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Top institutional shareholders of Doximity include FMR LLC (3.68%), Baillie Gifford & Co. (2.89%), State Street Corp (1.99%) and ArrowMark Colorado Holdings LLC (1.91%). Insiders that own company stock include Anna Bryson, Paul W Jorgensen, Craig Overpeck, Watkin Phoebe L Yang, Timothy S Cabral, Kira Scherer Wampler and Gilbert H Kliman. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Doximity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Doximity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), CrowdStrike (CRWD), PayPal (PYPL) and Invesco QQQ (QQQ). Company Calendar Last Earnings11/09/2021Today11/24/2024Next Earnings (Estimated)2/13/2025Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryComputer Software Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Stock Price Target$52.27 High Stock Price Target$75.00 Low Stock Price Target$32.00 Potential Upside/Downside+8.4%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$0.87 Trailing P/E Ratio55.40 Forward P/E Ratio56.05 P/E Growth3.89Net Income$147.58 million Net Margins33.69% Pretax Margin43.79% Return on Equity19.79% Return on Assets16.86% Debt Debt-to-Equity RatioN/A Current Ratio7.24 Quick Ratio7.24 Sales & Book Value Annual Sales$516.85 million Price / Sales17.41 Cash Flow$0.93 per share Price / Cash Flow52.04 Book Value$5.15 per share Price / Book9.36Miscellaneous Outstanding Shares186,692,000Free Float116,869,000Market Cap$9.00 billion OptionableNot Optionable Beta1.30 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:DOCS) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Doximity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.